Investigating ways to reverse chronic lung scarring caused by aging cells
Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis
This study is looking at how certain aging cells in the lungs affect idiopathic pulmonary fibrosis (IPF) and is testing a new compound called F-4N that might help clear these cells and improve lung health for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11076654 on NIH RePORTER |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by scarring and limited treatment options. The study aims to understand how certain aging cells in the lungs contribute to this condition and explores the use of a novel flavonoid compound, F-4N, which has shown promise in clearing these aging cells and reducing lung fibrosis in animal models. By targeting specific signaling pathways involved in cell aging, the research seeks to develop effective therapies for patients suffering from IPF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis, particularly those experiencing accelerated aging symptoms in their lungs.
Not a fit: Patients with other forms of lung disease or those not diagnosed with idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve lung function and quality of life for patients with chronic pulmonary fibrosis.
How similar studies have performed: Previous research has shown success with similar approaches targeting senescent cells in other conditions, indicating potential for this novel treatment strategy.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Haak, Andrew Jon — Mayo Clinic Rochester
- Study coordinator: Haak, Andrew Jon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.